Gapping up
In reaction to earnings/guidance:
- NE +4% (guidance), SYF +2.5%
Other news:
- PLRX +74.8% (reports positive data from the INTEGRIS-IPF Phase 2a trial demonstrating Bexotegrast 320 mg was well tolerated and achieved statistically significant FVC increase)
- AQUA +16.5% (to be acquired by Xylem in $7.5 bln all-stock transaction)
- HCM +8.5% (Takeda (TAK) to acquire exclusive worldwide (ex-China) license of HUTCHMED's Fruquintinib)
- CLLS +8.5% (amends $20 mln convertible note under collaboration agreement with its partner Cytovia Therapeutics)
- IDCC +7.4% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $200 million of its common stock at $60.00-69.00)
- SPOT +4.5% (announced a reduction in the Company's employee base by about 6%)
- WDC +4.1% (merger discussions with Kioxia Holdings are progressing according to Bloomberg)
- SGML +3.2% (announces initiation of commissioning of Dense Medium Separation processing plant and go forward leadership as it evolves to lithium producer)
- SMR +2.5% (positive Barron's article)
- ASML +2.1% (positive Barron's article) TV +1.6% (positive Barron's article)
- SI +1.3% (reports that exposure to Genesis was limited with deposit relationship under $2.5 mln)
- HMC +1% (signed a memorandum of understanding with GS Yuasa International for collaboration in a high-capacity and high-output Lithium-ion Battery)
Analyst comments:
- SHOP +4.7% (upgraded to Buy from Hold at Deutsche Bank)
- SWKS +2.8% (upgraded to Overweight from Equal Weight at Barclays)
- AMD +2.5% (upgraded to Overweight from Equal Weight at Barclays)
- QCOM +2.1% (upgraded to Overweight from Equal Weight at Barclays)
- STX +1.9% (upgraded to Overweight from Equal Weight at Barclays)
- SHC +1.1% (upgraded to Neutral from Underweight at JP Morgan)